News

Techalt, Inc.'s Stan's Rodeo Ointment (SRO) has Successful Introduction at the 2008 Beijing Olympics

SEATTLE-(Business Wire)-September 5, 2008 - Techalt, Inc. (Pink Sheets:TCLT) ("Techalt" or "Company") announced that Stan’s Rodeo Ointment (“SRO”) was dispensed for use by athletes at the 2008 Beijing Olympic Games. SportPharm, SRO’s compounder, and a U.S. Food and Drug Administration (“FDA”) licensed distributor, and subsidiary of HNP Pharmaceuticals, operated as a member of the U.S. Olympic Medical Team and featured SRO for the Olympic athletes and staff use at the Games.

Mike Pavlovich, Chief Pharmacist at SportPharm, conveyed his excitement about the use of SRO at the Olympics and the positive feedback he received. Pavlovich stated, “SRO was well received. I spent a morning educating a number of Medical Doctors and ATC’s (Athletic Trainers Certified) about our various compounds. SRO and Stan’s Skin Toughner (SST) was used by the U.S. Olympic weightlifting, baseball and track teams. In fact, one weightlifting coach commented that he has a gym with '500' clients, and SRO would be a natural complement.”

Techalt is excited about SRO’s contribution to the 2008 Beijing Olympics. Techalt believes SRO will not only continue to penetrate the professional athlete market, but expects to soon establish a base in colleges, universities and high school campuses nationwide. In connection with a marketing campaign specifically targeted to collegiate and scholastic athletics.

Techalt has secured financing for expanding SRO’s distribution channels, securing contracts and obtaining over the counter approval from the FDA.

About Techalt:

Techalt is a public holding company structured and designed to pursue business in start-ups and developing, early to mid-stage alternative technology, communications, environmental and health and wellness companies.

About Stan’s Rodeo Ointment (“SRO”):

SRO, currently available by prescription only, is a sports cream product designed to accelerate the healing time for abrasions, lacerations and blisters of the skin, while diminishing the pain that often results from such injuries. Patent protection has been filed covering the formulations and processing of SRO with the US Patent and Trademark Office with a patent expected in 2008. For more information about SRO and related products, access the link below:

http://www.sportpharm.com/stans/index.php

About HNP Pharmaceuticals (“HNP”):

HNP Pharmaceuticals is a nationally recognized pharmaceutical compounding laboratory, specializing in unique and patent-pending compounded formulations for orthopedic injuries. For more information about HNP, access the link below:

http://www.hnppharmaceuticals.com/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("the Exchange Act"), as such, may involve risks and uncertainties. Forward-looking statements are based upon certain assumptions and describe future plans, strategies and expectations, are generally identifiable by the use of words as "believe," "expect," "intend," "anticipate," "project," or other similar expressions. Forward-looking statements relate to, among other things, future performance, and perceived opportunities in the market and statements regarding the Company's mission and vision. The Company's actual results, performance and achievements may differ materially from the results, performance, and achievements expressed or implied in such forward-looking statements. Additional factors that could materially affect these forward-looking statements and/or predictions include, among other things: (1) its ability to manage and complete acquisitions and to expand of operations; (2) obtaining necessary financing to expands operations and manage existing debt; (3) compliance with federal, state and local government and international regulations; and (4) other factors over which we have little or no control.

Send this news item to a friend.

Print This Page